---
layout: default
title: Pegvisomant
parent: 僅模型預測 (L5)
nav_order: 518
evidence_level: L5
indication_count: 10
---

# Pegvisomant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pegvisomant: From GH Receptor Antagonist Therapy to Borderline Ovarian Serous Tumour

## One-Sentence Summary

Pegvisomant (DrugBank DB00082) is a growth hormone receptor antagonist that blocks the GH–IGF-1 axis; its specific original approved indication is not captured in this evidence pack (flagged as a data gap, see below). The TxGNN model predicts a possible signal for **Borderline Ovarian Serous Tumour**, but this is currently supported by **0 clinical trials** and **0 publications** — the prediction rests on model similarity alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack (Data Gap DG002 — MOA/indication needs DrugBank verification) |
| Predicted New Indication | Borderline ovarian serous tumour |
| TxGNN Prediction Score | 98.63% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Pegvisomant is not available in this evidence pack. Based on the information present in the model's own rationale output, Pegvisomant acts as a growth hormone (GH) receptor antagonist, blocking the GH–IGF-1 signalling axis. IGF-1 signalling has a theoretical, general link to proliferation in some ovarian epithelial tumours, which is presumably the basis for this prediction — but no direct evidence (trial or published) connects Pegvisomant to borderline serous ovarian tumours specifically.

Two features of this evidence pack warrant caution rather than support. First, 6 of the top 10 predicted indications (ranks 1, 2, 3, 5, 7, 8, 9, 10) are all ovarian neoplasms, most of them rare and benign — the model's own annotations note this repetition "may reflect a systematic scoring bias toward the 'ovarian tumour' semantic cluster rather than individually validated mechanistic links." Second, unrelated conditions also appear in the top 10 with implausible mechanisms (pyelonephritis at rank 4, aleukemic mast cell leukemia at rank 6), both explicitly annotated as having little to no biological rationale. Taken together, this indicates the current ranking reflects embedding-space proximity rather than validated pharmacology, consistent with the L5 evidence level assigned to every candidate.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Australia Market Information

Pegvisomant is **not currently marketed in Australia** — there are no ARTG entries on record (0 licences), so no TGA-approved product information exists to reference for this drug at present.

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. Note that since Pegvisomant is not currently registered in Australia, no TGA PI exists yet — overseas labelling (e.g. FDA/EMA information for Somavert) would need to be sourced directly. Warnings, contraindications, and drug-interaction data are currently a **Blocking** data gap (DG001) that prevents this candidate from entering even an initial safety screen.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All 10 predicted indications are supported only by TxGNN model output (L5), with zero clinical trials or literature identified across systematic searches, and the top-ranked candidate's own rationale flags a possible clustering bias rather than validated mechanism. Combined with the drug being unregistered in Australia and a Blocking gap on safety/warning data, there is currently no basis to advance beyond model prediction.

**To proceed, the following is needed:**
- TFDA/TGA product information (warnings, contraindications) — Blocking gap (DG001)
- Confirmed original indication and mechanism of action from DrugBank/product labelling — High-priority gap (DG002)
- Preclinical or mechanistic studies specifically linking the GH–IGF-1 axis to borderline ovarian serous tumour pathophysiology
- Any real-world evidence (case reports, registry data) given the complete absence of trials or publications at this time
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

